Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
151 hedge funds and large institutions have $1.08B invested in Chinook Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 15 closing their positions.
3,211% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $307K
133% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 30
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
21% more capital invested
Capital invested by funds: $898M → $1.08B (+$186M)
12% more funds holding
Funds holding: 135 → 151 (+16)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$20.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.3M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$13.7M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.4M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.8M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$13.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.63M |
| 4 |
VA
VR Adviser
New York
|
-$8.56M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$7.91M |
KDNY Hedge Fund Activity: Q3 2022 in Review
151 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2022, worth a combined $1.08B — up 21% from $898M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new KDNY positions and 15 closed out — a net gain of 16 holders — while 70 added to existing stakes and 30 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $20.6M. The largest seller was Millennium Management, cutting an estimated $15.8M.
- 151 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2022, up from 135 in Q2 2022.
- Funds reported $1.08B of Chinook Therapeutics, Inc. Common Stock stock for Q3 2022, up 21% quarter-over-quarter.
- 31 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2022 and 15 closed out, a net change of +16 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2022 was Victory Capital Management, an estimated $20.6M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q3 2022.